The Latest Cardiac and Vascular News
LONDON–(BUSINESS WIRE)–Feb. 25, 2020– LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device modification to its 3T Heater-Cooler® devices. The modification includes the installation of a 3T Aerosol Collection Set, as well as testing that demonstrates the effectiveness of […]
LONDON–(BUSINESS WIRE)–Feb. 26, 2020– LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019. For the fourth quarter of 2019, worldwide sales were $287.6 million, a decrease of 3.2 percent on a reported basis and a decrease of 2.2 percent on a […]
ENGLEWOOD, Colo., Feb. 27, 2020 /PRNewswire/ — 2019 Full Year Revenue increased 42% year over year to $45.5 million Net income $9.5 million; Diluted EPS $0.28 2019 Revenue, net income and Adjusted EBITDA are the highest in Company history Adjusted EBITDA increased 11% to $12.1M 2019 Fourth Quarter Revenue increased 52% year over year to $14.2 million […]
Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation SAN DIEGO, Feb. 28, 2020 /PRNewswire/ — HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, has presented the results of a Phase I study of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF). […]
LONG BEACH, Calif., Feb. 27, 2020 /PRNewswire/ — The MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the only hospital in Southern California — and one of only four sites in all of California — participating in the Dual Epicardial and Endocardial Procedure clinical trial (DEEP). The trial is a prospective, multi-center, single-arm, investigational device […]
BRISBANE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the fourth quarter and full year ended December 31, 2019. “MyoKardia achieved significant progress in 2019, advancing our pipeline and regaining global rights to our entire portfolio. There were important data readouts across […]
– REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplastic syndromes indication is ongoing – – Multiple clinical presentations reviewed at the […]
EDEN PRAIRIE, Minn., Feb. 26, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced FDA 510(k) clearance in the U.S. of its next generation Aquadex SmartFlow console for use in adult and pediatric patients who weigh 20kg or more. The console is a simple, gentle, and smart solution for treatment of patients suffering from hypervolemia […]
Resuscitation programs and education for fire service leaders are central elements to improve survival rates DALLAS, Feb. 27, 2020 /PRNewswire/ — The American Heart Association states more than 350,000 out-of-hospital cardiac arrests occur in the United States annually. About 90% of people who experience an out-of-hospital cardiac arrest die. A time-critical, life-threatening condition, out-of-hospital cardiac arrest […]
ZURICH, Feb. 27, 2020 /PRNewswire/ — Neurimmune AG, the discoverer of aducanumab and cinpanemab, announced today enrollment of the first patient in a Phase 1 clinical trial to evaluate NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy). NI006 is a human antibody directed against transthyretin amyloid (TTR amyloid) consisting of misfolded and aggregated […]
